Covidien deals Stellarex balloon to Spectranetics for $30m - MassDevice
PDF) Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: 12-Month Outcomes from the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies
Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex 0.035 low-dose DCB - Vascular News